Drug Profile
Maralixibat - Mirum Pharmaceuticals
Alternative Names: CAN 108; GC-2127A; LIVMARLI; Lopixibat - Mirum Pharmaceuticals; Lopixibat chloride - Mirum Pharmaceuticals; LUM-001; Maralixibat chloride - Mirum Pharmaceuticals; SD-5613; SHP 625; TAK-625Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer CANbridge Pharmaceuticals; GC Biopharma; Mirum Pharmaceuticals; Pfizer; Takeda
- Class Amines; Anti-inflammatories; Antihyperlipidaemics; Azabicyclo compounds; Benzothiepins; Dioxoles; Hepatoprotectants; Onium compounds; Small molecules
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alagille syndrome; Intrahepatic cholestasis
- Phase II Biliary atresia
- Discontinued Hypercholesterolaemia; Primary biliary cirrhosis; Primary sclerosing cholangitis
Most Recent Events
- 13 Mar 2024 Mirum Pharmaceuticals files sNDA for Maralixibat higher concentration formulation for Intrahepatic cholestasis for younger patients in USA
- 13 Mar 2024 Launched for Intrahepatic cholestasis (In adolescents, In children, In adults) in USA (PO)
- 13 Mar 2024 Registered for Intrahepatic cholestasis (In adolescents, In children, In adults) in USA (PO)